Efficacy and safety of NT 201, botulinum neurotoxin type A free from complexing proteins) in pre-treated cervical dystonia patients

被引：0
|
作者：
Grafe, S.
Comella, C.
Jankovic, J.
Truong, D.
Hanschmann, A.
机构：
来源：
MOVEMENT DISORDERS | 2009年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S92 / S92
页数：1
相关论文
共 50 条
  • [41] Different dilutions of NT 201 (Xeomin®, botulinum neurotoxin free from complexing proteins) is efficacious and well-tolerated in upper limb spasticity of various etiologies
    Barnes, M. P.
    Schnitzler, A.
    Silva, A. Amaral e
    Aguilar, M.
    Lehnert-Batar, A.
    Minnasch, R.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S75 - S75
  • [42] Repeated treatments with NT 201 (Xeomin®; Botulinum neurotoxin type A free from complexing proteins) are safe and effective for up to 89 weeks in upper limb post-stroke spasticity
    Kanovsky, P.
    Pulte, I.
    Comes, G.
    Grafe, S.
    JOURNAL OF NEURAL TRANSMISSION, 2010, 117 (10) : 1236 - 1236
  • [43] Safety and efficacy of neurobloc™ (botulinum toxin type B) in type a responsive cervical dystonia patients
    Brashear, A
    Lew, MF
    Dykstra, DD
    Comella, CL
    Factor, SA
    Rodnitzky, RL
    Trosch, R
    Singer, C
    Brin, MF
    Murray, JJ
    Willmer-Hulme, A
    Wallace, JD
    Koller, M
    NEUROLOGY, 1999, 52 (06) : A292 - A293
  • [44] A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins
    Jimenez-Shahed, Joohi
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2012, 8 : 13 - 25
  • [45] Neurophysiological double-blind trial of a botulinum neurotoxin type A free of complexing proteins
    Wohlfarth, Kai
    Mueller, Christian
    Sassin, Irena
    Comes, Georg
    Grafe, Susanne
    CLINICAL NEUROPHARMACOLOGY, 2007, 30 (02) : 86 - 94
  • [46] Safety and efficacy of Neurobloc™ (botulinum toxin type B) in type a resistant cervical dystonia (CD) patients
    Brin, MF
    Lew, MF
    Adler, CH
    Comella, CL
    Factor, SA
    Jankovic, J
    O'Brien, CF
    Murray, JJ
    Wallace, JD
    Willmer-Hulme, A
    Koller, M
    NEUROLOGY, 1999, 52 (06) : A293 - A293
  • [47] Comparison of the safety and efficacy of botulinum toxin type-A and anticholinergics in the treatment of cervical dystonia patients
    Relja, M.
    Bozikov, J.
    MOVEMENT DISORDERS, 2015, 30 : S520 - S520
  • [48] Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
    Maio, M.
    Danielli, R.
    Chiarion-Sileni, V.
    Pigozzo, J.
    Parmiani, G.
    Ridolfi, R.
    De Rosa, F.
    Del Vecchio, M.
    Di Guardo, L.
    Queirolo, P.
    Picasso, V.
    Marchetti, P.
    De Galitiis, F.
    Mandala, M.
    Guida, M.
    Simeone, E.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2013, 24 (11) : 2911 - 2915
  • [49] Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia
    Brin, MF
    Lew, MF
    Adler, CH
    Comella, CL
    Factor, SA
    Jankovic, J
    O'Brien, C
    Murray, JJ
    Wallace, JD
    Willmer-Hulme, A
    Koller, M
    NEUROLOGY, 1999, 53 (07) : 1431 - 1438
  • [50] Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia
    Brashear, A
    Lew, MF
    Dykstra, DD
    Comella, CL
    Factor, SA
    Rodnitzky, RL
    Trosch, R
    Singer, C
    Brin, MF
    Murray, JJ
    Wallace, JD
    Willmer-Hulme, A
    Koller, M
    NEUROLOGY, 1999, 53 (07) : 1439 - 1446
12345